SCHEMBL8345568

SCHEMBL8345568

Cc1ccccc1NC(=O)C(NC(=O)OC(C)(C)C)C(C)(C)C

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 2/20 0.45
RAB9A P51151 2/20 0.45
HPGD P15428 3/20 0.44
ALDH1A1 P00352 3/20 0.44
MAPT P10636 3/20 0.44
SMN1; SMN2 Q16637 1/20 0.44
LMNA P02545 3/20 0.43
POLB P06746 2/20 0.43
PGR P06401 1/20 0.43
SCN1A P35498 1/20 0.43
SCN2A Q99250 1/20 0.43
SCN3A Q9NY46 1/20 0.43
PDK1 Q15118 1/20 0.43
PDK2 Q15119 1/20 0.43
PDK3 Q15120 1/20 0.43
PDK4 Q16654 1/20 0.43
TSHR P16473 1/20 0.42
GAA P10253 2/20 0.42
HSD17B10 Q99714 2/20 0.42
TP53 P04637 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8347768 0.90 LMNA (0.47) NPC1RAB9AHPGDALDH1A1MAPT
SCHEMBL8345117 0.85 CTSS (0.51) NPC1RAB9AHPGDALDH1A1MAPT
SCHEMBL8344155 0.85 CTSS (0.51) NPC1RAB9AHPGDALDH1A1MAPT
SCHEMBL8347951 0.85 CTSS (0.51) NPC1RAB9AHPGDALDH1A1MAPT
SCHEMBL8347748 0.85 PGR (0.53) NPC1RAB9AHPGDALDH1A1MAPT
SCHEMBL8348009 0.82 CTSS (0.60) NPC1RAB9AHPGDALDH1A1MAPT
SCHEMBL8337352 0.82 CTSS (0.60) NPC1RAB9AHPGDALDH1A1MAPT
SCHEMBL1534089 0.81 NPC1 (0.58) NPC1RAB9AHPGDALDH1A1MAPT
SCHEMBL8345787 0.79 CTSS (0.64) MAPTSMN1; SMN2POLBCTSSCTSK
SCHEMBL8338013 0.77 KMT2A (0.58) MAPTTSHRL3MBTL1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2004022534-A1 ARYLGLYCINE DERIVATIVES FOR USE AS GLYCINE TRANSPORT INHIBITORS NPS ALLELIX CORP. (CA) 2004-03-18 WO disclosed